Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study

Abstract Background There are limited data from low‐ to middle‐income countries (LMIC) on the incidence, risk factors, treatment outcomes, and antibiotic susceptibility spectrum of aspiration pneumonia (AsP). Methods We conducted a post hoc analysis of a randomized control trial in which adult patie...

Full description

Bibliographic Details
Main Authors: Vijay Patil, Vanita Noronha, Sameer Shrirangwar, Nandini Menon, George Abraham, Arun Chandrasekharan, Kumar Prabhash
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.4210
id doaj-8865fbf185594cc1b02bbbbd7bdbbe4c
record_format Article
spelling doaj-8865fbf185594cc1b02bbbbd7bdbbe4c2021-10-07T06:35:32ZengWileyCancer Medicine2045-76342021-10-0110196725673510.1002/cam4.4210Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 studyVijay Patil0Vanita Noronha1Sameer Shrirangwar2Nandini Menon3George Abraham4Arun Chandrasekharan5Kumar Prabhash6Department of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaDepartment of Medical Oncology Tata Memorial CentreHBNI Mumbai IndiaAbstract Background There are limited data from low‐ to middle‐income countries (LMIC) on the incidence, risk factors, treatment outcomes, and antibiotic susceptibility spectrum of aspiration pneumonia (AsP). Methods We conducted a post hoc analysis of a randomized control trial in which adult patients with locally advanced head and neck cancers had received 66–70 Gy of radiation combined with cisplatin 30 mg/m2 weekly for 6–7 weeks or cisplatin at the same dose with nimotuzumab 200 mg once weekly till the completion of radiation. The following data were extracted and analyzed—the incidence of AsP, time to the onset of AsP, risk factors, treatment outcomes of AsP, and its impact on progression‐free survival (PFS), locoregional control (LRC) rates, and overall survival (OS). Results Out of 536 patients enrolled in the study, 151 (28.3%, 95% confidence interval [CI] 24.5–2.1) patients developed AsP. The median time to develop AsP was 39 days (95% CI 34–44). Only baseline dysphagia (odds ratio = 3.76, 95% CI 1.05–13.51, p = 0.042) was associated with a significant risk of development of AsP. Among the patients in which pathogenic organism was isolated (69 patients), gram‐negative species was isolated in 63 patients (89%). Cisplatin at 200 mg/m2 or more was delivered in 312 (81%) patients in the non‐AsP cohort versus 107 (70.9%) patients in AsP cohort (p = 0.014). There was no statistical difference in LRC (hazard ratio [HR] = 1.057; 95% CI 0.771–1.448), PFS (HR = 1.176; 95% CI 0.89–1.553), and OS (HR = 1.233; 95% CI 0.939–1.618) between the two cohorts. Conclusion Aspiration pneumonia is a common complication in head and neck malignancies and patients with baseline dysphagia are at high risk. Gram‐negative bacteria are the predominant causative agents. The use of broad‐spectrum antibiotics results in resolution of symptoms.https://doi.org/10.1002/cam4.4210adverse eventaspiration pneumoniachemoradiationcomplicationhead and neck cancer
collection DOAJ
language English
format Article
sources DOAJ
author Vijay Patil
Vanita Noronha
Sameer Shrirangwar
Nandini Menon
George Abraham
Arun Chandrasekharan
Kumar Prabhash
spellingShingle Vijay Patil
Vanita Noronha
Sameer Shrirangwar
Nandini Menon
George Abraham
Arun Chandrasekharan
Kumar Prabhash
Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
Cancer Medicine
adverse event
aspiration pneumonia
chemoradiation
complication
head and neck cancer
author_facet Vijay Patil
Vanita Noronha
Sameer Shrirangwar
Nandini Menon
George Abraham
Arun Chandrasekharan
Kumar Prabhash
author_sort Vijay Patil
title Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
title_short Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
title_full Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
title_fullStr Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
title_full_unstemmed Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
title_sort aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from india: findings from a post hoc analysis of a phase 3 study
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2021-10-01
description Abstract Background There are limited data from low‐ to middle‐income countries (LMIC) on the incidence, risk factors, treatment outcomes, and antibiotic susceptibility spectrum of aspiration pneumonia (AsP). Methods We conducted a post hoc analysis of a randomized control trial in which adult patients with locally advanced head and neck cancers had received 66–70 Gy of radiation combined with cisplatin 30 mg/m2 weekly for 6–7 weeks or cisplatin at the same dose with nimotuzumab 200 mg once weekly till the completion of radiation. The following data were extracted and analyzed—the incidence of AsP, time to the onset of AsP, risk factors, treatment outcomes of AsP, and its impact on progression‐free survival (PFS), locoregional control (LRC) rates, and overall survival (OS). Results Out of 536 patients enrolled in the study, 151 (28.3%, 95% confidence interval [CI] 24.5–2.1) patients developed AsP. The median time to develop AsP was 39 days (95% CI 34–44). Only baseline dysphagia (odds ratio = 3.76, 95% CI 1.05–13.51, p = 0.042) was associated with a significant risk of development of AsP. Among the patients in which pathogenic organism was isolated (69 patients), gram‐negative species was isolated in 63 patients (89%). Cisplatin at 200 mg/m2 or more was delivered in 312 (81%) patients in the non‐AsP cohort versus 107 (70.9%) patients in AsP cohort (p = 0.014). There was no statistical difference in LRC (hazard ratio [HR] = 1.057; 95% CI 0.771–1.448), PFS (HR = 1.176; 95% CI 0.89–1.553), and OS (HR = 1.233; 95% CI 0.939–1.618) between the two cohorts. Conclusion Aspiration pneumonia is a common complication in head and neck malignancies and patients with baseline dysphagia are at high risk. Gram‐negative bacteria are the predominant causative agents. The use of broad‐spectrum antibiotics results in resolution of symptoms.
topic adverse event
aspiration pneumonia
chemoradiation
complication
head and neck cancer
url https://doi.org/10.1002/cam4.4210
work_keys_str_mv AT vijaypatil aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT vanitanoronha aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT sameershrirangwar aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT nandinimenon aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT georgeabraham aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT arunchandrasekharan aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
AT kumarprabhash aspirationpneumoniainheadandneckcancerpatientsundergoingconcurrentchemoradiationfromindiafindingsfromaposthocanalysisofaphase3study
_version_ 1716839580847570944